Cabaletta Bio prices $150M stock offering to fund autoimmune cell therapies
What's the deal? Cabaletta Bio, a clinical-stage biotech developing cell therapies for autoimmune diseases, has priced an underwritten offering of 51.7 million shares of common stock at $2.90 per share. The deal is expected to bring in roughly $150 million in gross proceeds before fees.
The Philadelphia-based company, listed on Nasdaq under the ticker CABA, expects the offering to close on or about May 5, 2026. TD Cowen, Guggenheim Securities, and Cantor are acting as joint book-running managers.
Investors include Bain Capital Life SciencesDealroom has a profile for this one. Try Dealroom →, Adage Capital Management, Cormorant Asset Management, and other existing backers, alongside multiple new mutual funds, sovereign wealth funds, and pharma giant Eli Lilly.
Why now? Cabaletta is running clinical trials for rese-cel, an investigational CD19-CAR T cell therapy, across four autoimmune conditions: lupus, myositis, systemic sclerosis, and pemphigus vulgaris. All four trials are currently recruiting patients, suggesting the company needs capital to sustain momentum as it pushes toward later-stage results.
The $2.90 per share price represents the at-the-market price under Nasdaq rules, meaning the company is raising at current market value rather than a premium — a common move for clinical-stage biotechs that need to keep funding flowing without spooking existing shareholders.
What could go wrong? Clinical-stage biotechs carry inherent risk. Rese-cel has yet to prove efficacy at scale, and any setback in its four ongoing trials could undermine investor confidence. The offering also dilutes existing shareholders by adding over 51 million new shares to the float.
Cell therapy manufacturing is notoriously complex and expensive. Even with $150 million in fresh capital, Cabaletta will need to demonstrate clear clinical progress to justify further fundraising down the line.
The signal: The participation of Eli Lilly and sovereign wealth funds alongside specialist life sciences investors like Bain Capital Life Sciences underscores broadening institutional conviction that CAR-T technology can extend beyond oncology into autoimmune disease. Cabaletta's ability to raise $150 million at market price, despite being pre-revenue and running four concurrent trials, suggests the autoimmune cell therapy space is drawing the kind of deep-pocketed, long-horizon capital typically reserved for more mature programmes.
Read more: cabalettabio.com
